Nandhini J., Rajalakshmi A. N.*
Department of Pharmaceutics, College of Pharmacy, Mother Theresa Post Graduate and Research Institute of Health Sciences, Puducherry, India.
*Address for Corresponding Author
Dr. A. N. Rajalakshmi,
HOD Department of Pharmaceutics,
College of Pharmacy,
Mother Theresa Post Graduate and Research Institute of Health Sciences, Puducherry, India.
Abstract
Objective: The objective of this study was to enhance the solubility of methylprednisolone by choosing micronized form of drug and to enhance patient compliance by formulating it as dispersible tablets. Materials and methods: Methylprednisolone dispersible tablets were prepared by direct compression method using micronized form of drug. The concentration of magnesium stearate and superdisintegrants such as croscarmellose sodium and sodium starch glycolate were varied and the concentration of other excipients was kept constant. Formulated dispersible tablets were evaluated for uniformity of dispersion, invitro dispersion time, wetting volume, in vitro disintegration time, in vitro dissolution profile, wetting time and water absorption ratio. Results: Results showed that no significant drug-polymer interactions in FTIR studies. Among all the formulations F3 containing croscarmellose sodium showed superior micromeritic properties along with excellent in vitro disintegration time of 45sec and 100% drug release within 20min as compared to other formulations. Stability study on optimized F3 formulation showed that there is no significant change during study period. F3 formulation was found to be stable. Conclusion: Thus for better patient compliance and reduced developmental cost micronisation and superdisintegrants addition turns out to be a best option.
Keywords: Dispersible tablets, Methylprednisolone, Croscarmellose Sodium and Sodium Starch Glycolate
